Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Post-Operative Nausea And Vomiting Market Size from 2025 to 2034?
In recent years, the market for post-operative nausea and vomiting has witnessed significant growth. The market is projected to expand from $2.11 billion in 2024 to $2.25 billion in 2025, recording a compound annual growth rate (CAGR) of 6.8%. The growth in the previous period is credited to increased research and development activities, rising demand for innovative therapies, a surge in healthcare spending, a heightened emphasis on personalized medicine, and wider adoption of digital health technologies.
Over the coming years, the market size of post-operative nausea and vomiting is projected to experience robust growth, reaching$2.94 billion by 2029, escalating at a compound annual growth rate (CAGR) of 6.9%. This growth in the forecast period is due to a number of factors including an increasing demand for pharmaceuticals, the rise of combination therapy, elevated healthcare investments, growing awareness, an aging population, and an increase in cancer cases. Trends in this forecast period encompass advanced antiemetic therapies, strategic partnerships, novel drug formulations, the incorporation of high-tech diagnostic tools and electronic simulation devices.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp
What Are the Core Market Drivers Propelling Growth in the Post-Operative Nausea And Vomiting Industry?
The increase in surgical procedures is anticipated to boost the expansion of the market for post-operative nausea and vomiting. Surgical procedures in medicine are defined as operations using tools to identify, cure, or eradicate unhealthy tissue, organs, or irregularities by cutting or manipulation. Today, the rate of surgeries is accelerating due to the breakthroughs in medical innovation, making surgical procedures more patient-friendly, efficient, and less intrusive, thus increasing wider adoption and patient trust. Post-operative nausea and vomiting control heighten the effectiveness of surgical procedures by enhancing patient comfort, shortening recovery span, lessening the chance of complications, ensuring better post-operative supervision, and eventually, improving the overall results of the surgery. For example, as reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in the period of 2023-24, there was a 4.9% increase in patients admitted for surgery from public hospital elective surgery waiting lists. This was as many as 771,600 patients comparing to the figures of 2022–23. Conclusively, the surge in surgical procedures is fostering the expansion of the market for post-operative nausea and vomiting.
How Is the Post-Operative Nausea And Vomiting Market Segmented?
The post-operative nausea and vomitingmarket covered in this report is segmented –
1) By Treatment Type: Serotonin Antagonists; Steroids; Dopamine Antagonists; Neurokinin NK-1 Receptor Antagonists; Non-pharmacological Treatment; Other Treatment Types
2) By Route Of Administration: Oral; Intravenous; Transdermal; Other Route Of Administrations
3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients
4) By Surgical Procedure Type: Orthopedic Surgery; Gynecological Surgery; General Surgery; Cardiac Surgery; Ophthalmic Surgery
5) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users
Subsegments:
1) By Serotonin Antagonists Type: Ondansetron; Granisetron; Palonosetron; Dolasetron; Tropisetron
2) By Steroids Type: Dexamethasone; Methylprednisolone; Hydrocortisone; Prednisolone; Betamethasone
3) By Dopamine Antagonists Type: Metoclopramide; Droperidol; Prochlorperazine; Domperidone; Chlorpromazine
4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant; Fosaprepitant; Rolapitant; Netupitant; Casopitant
5) By Non-Pharmacological Treatment Type: Acupressure; Aromatherapy; Hypnotherapy; Electroacupuncture; Ginger Supplements
6) By Other Treatment Types: Antihistamines; Anticholinergics; Cannabinoids; Combination Therapy; Herbal & Natural Remedies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp
Which Regions Are Driving the Next Phase of the Post-Operative Nausea And Vomiting Market Growth?
North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Post-Operative Nausea And Vomiting Industry?
Key players in the post-operative nausea and vomiting market are concentrating on the creation of crucial injectable medications via the utilization of advanced emulsion formulations and sustained-release technology. The aim is to enhance effectiveness and provide extended relief from symptoms for patients after surgery. These crucial injectable medications are essentially drugs administered through injection, intended to offer immediate and potent treatment for severe or emergency health conditions. For example, Avenacy, a specialty pharmaceutical company situated in the US, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials in July 2024. The aim was to assist healthcare professionals in minimising dosing errors and promoting patient safety. This injection is recommended for preventing nausea and vomiting induced by chemotherapy and for managing post-operative nausea and vomiting for up to 24 hours post surgery. This provides a trustworthy treatment alternative for patients susceptible to these conditions.
View the full report here:
How Is the Post-Operative Nausea And Vomiting Market Defined and What Are Its Core Parameters?
Post-operative nausea and vomiting (PONV) is a common complication that occurs within 24 to 48 hours after surgery, often resulting from anesthesia, pain medications, or the body’s response to surgical stress. It can significantly affect a patient’s recovery, causing discomfort, delayed healing, and an increased risk of complications like dehydration or electrolyte imbalance.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model